Strategy

Stark discusses pharma’s supply chain and the issues it is facing.

As the industry expands on areas of women’s health with large unmet medical needs, one biotech company is targeting local, vaginal inflammation, specifically for women undergoing IVF and to address other fertility- and reproductive tract-associated health conditions.

With an organization's future commercial success under its remit, the NPP function has rapidly progressed to a prominent role in the biopharma industry—but evidence-generation strategies must evolve with an eye toward emerging trends and technologies.

Disruptive strategies are essential to grow the pharma industry.

A phased launch approach may ultimately be more sustainable and enable maximum market penetration and commercial success with less upfront investment than traditional “go-for-broke” strategies.

Now with a seat at the table, growing accountability, and evolving competencies, medical affairs can use its far-reaching influence to change pharma for the better.

The pharmaceutical industry must have crisis communications prepared now to anticipate unforeseen events—especially those that impact public trust.

As we approach the one-year anniversary of the IRA being signed into law, questions remain about how the new law will reverberate changes across the biopharma industry.

Artificial intelligence may find a home in clinical trials and manufacturing in the coming years, but privacy, cyber security, and determining who owns the intellectual properties could pose challenges.

While large pharma investment in biotechs is down—as pharmas become more strategic in their selections—it is scarcely out, with the partnership dynamic between the two sides remaining strong.

There are clear pathways that biopharma companies can take to sustain growth and remain competitive.

When deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.

A discussion with medical leaders on the present and future state of this vital biopharmaceutical function.

Industry insights on how pharma is faring in tapping new innovations and approaches in digital health.

Using prescription digital therapeutics can lead to better outcomes for patients, making them a win-win for pharma and patients.

Regardless of engagement mode pursued, personalization is the key.

Sunil Verma, SVP, Global Head of Oncology, Medical, AstraZeneca discusses how the Medical Affairs role will become more strategic and effective with data.

Looking at corporate value through a portfolio lens provides an astute and reliable path to genuine value creation.

Global medical affairs teams seek better support to manage relationships with key opinion leaders—and find that balance between patient needs, scientific objectives, and the interest areas of KOLs.

Pharm Exec spoke with Skalicky about new ways that life sciences companies are engaging with outsourcing.

Author Deepa Purushothaman discusses the progress of women and women of color in corporate America.

Pete O'Heeron, founder, chairman, and CEO of FibroBiologics, explains the key principles that biotechnology companies should follow.

Michael Ku, VP of global clinical supply at Pfizer, shares insights for the c-suite as well as reveals behind-the-scenes insight into Pfizer’s ability to deliver a COVID-19 vaccine swiftly.

A clearer understanding of the Inflation Reduction Act’s implications is needed for manufacturers to plot a successful course forward.

Rocket Pharmaceutical's CEO and CTO spoke with Pharm Exec about adding a new position to the company's C-suite.

Life sciences companies are collaborating more with technology enterprises, universities, and other groups, which is changing the landscape of the industry.

Barnes discusses alternative reimbursement plans for expensive, one-off therapies.

How pharma companies can make sure their corporate strategy in ESG is appealing to younger generations—and aligns with the issues this large segment of sustainability investors care about most.

Corrigan discusses the importance of a patient-centric approach.

Patients with Crohn's disease and ulcerative colitis face a high disease burden.